Takeda is entering one of the most pivotal moments in its 245-year history, with a late-stage pipeline poised to transform patient outcomes across three therapeutic areas. Chief Scientific Officer Chris Arendt goes Inside the ICE House to discuss the science behind drug candidates targeting narcolepsy, polycythemia vera, and psoriasis. He explores how AI and computational technologies are reshaping drug discovery and why building the right data foundation is critical to supercharging Takeda&#x27;s R&amp;D engine.

AI x Bio Series: Takeda CSO Chris Arendt on Transforming Drug Discovery & the R&D Pipeline

Inside the ICE House

Welcome into the Inside the ICE House podcast as we bring you our annual AI Biotech Series. Joining me on today's episode is Chris Arendt. He is the Chief Scientific Officer for Takeda. Chris, thanks so much for joining us inside the ICE House. Happy to have you here. What a pleasure, Eric. Thanks for this chance to speak with you today. So Chris, Takeda is a company with more than two centuries of history, but of course, focus of the organization from start to, as we said today in 2026, remains on obviously addressing some of the most challenging diseases facing problems.

facing patients, excuse me, around the world. Its mission statement, enduring purpose of delivering better health for people and a brighter future for the world. When I say that, right, and you think about your day to day and the problems that Takeda is taking on, the problems that Takeda is combating, how would you describe what that mission means to you and how it translates into what you and your team do each day? Yeah, well, thanks. I mean, at the center of that mission, right, is continuing to make a real difference for patients.

That is what has sustained Takeda for 245 years. And my mission is to make sure that doesn't stop now, but that we can take that ultimately to the next level. I mean, this is, and to do that across all of our therapeutic areas in Takeda, those are gastroenterology and inflammation, neuroscience and oncology.

And in each of these areas, there still is immense unmet medical needs, right? And we want to not only bring those next therapeutics to patients, but we want to deliver them to as many people across the world as we possibly can.

AI x Bio Series: Takeda CSO Chris Arendt on Transforming Drug Discovery & the R&D Pipeline

Read the full transcript

The candid version is on a podcast,
not the earnings call.

AI x Bio Series: Takeda CSO Chris Arendt on Transforming Drug Discovery & the R&D Pipeline

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.